Cite
HARVARD Citation
Massaro, F. et al. (2021). Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. British journal of haematology. pp. 1011-1014. [Online].